1434 Federal Register / Vol. 87, No. 7 / Tuesday, January 11, 2022 / Notices 

Shenzhen City Yaxin General 

Machinery Co., Ltd. Mot. at 1. Order No. 

12 (Nov. 6, 2020), unreviewed by Notice 

(Nov. 24, 2020); see 85 FR 77239–40 

(Dec. 1, 2020). The Commission 

terminated the investigation as to the 

following respondents based on consent 

orders and/or settlement agreements: 

Eddie Bauer LLC and PSEB Holdings, 

LLC; DHgate; Everich and Tomic 

Houseware Co., Ltd. Order No. 13 (Nov. 

30, 2020), unreviewed by Notice (Dec. 

21, 2020); Order No. 17 (Jan. 27, 2021), 

unreviewed by Notice (Feb. 16, 2021); 

Order No. 19 (Feb. 22, 2021), 

unreviewed by Notice (Mar. 12, 2021). 

The Commission also terminated the 

investigation with respect to the ’282 

trademark. Order No. 16 (Jan. 11, 2021), 

unreviewed by Notice (Feb. 8, 2021). 

On April 14, 2021, the Commission 

found the Defaulting Respondents in 

default. Order No. 21 (Mar. 22, 2021), 

unreviewed by Notice (Apr. 14, 2021). 

The Commission also permitted Hydro 

Flask to withdraw the amended 

complaint as to the remaining 

respondents: HydroFlaskPup, Yiwu 

Honglu Daily Necessities Co., Ltd., and 

Yiwu Houju E-commerce Firm. Order 

No. 22 (Apr. 7, 2021), unreviewed by 

Notice (Apr. 22, 2021). 

On April 8, 2021, Hydro Flask filed a 

motion for summary determination of a 

violation of section 337 pursuant to 

Commission Rules 210.16(c)(2), 210.18 

(19 CFR 210.16(c)(2), 210.18) to support 

its request for entry of a GEO with 

respect to all asserted patents and 

trademarks. On August 9, 2021, OUII 

filed a response in support of the 

motion. 

On September 3, 2021, the presiding 

chief administrative law judge (‘‘CALJ’’) 

issued an initial determination (‘‘ID’’) 

granting in part Hydro Flask’s motion 

for summary determination. The ID 

finds that Hydro Flask has shown by 

reliable, probative, and substantial 

evidence that a violation of section 337 

has occurred with respect to the ’784, 

’365, and ’888 trademarks, and the 

D’468, D’012, and D’320 patents, and 

that the domestic industry requirement 

is satisfied for the infringed trademarks 

and patents. The ID finds that a 

violation has been established with 

respect to ten out of thirteen defaulting 

respondents: Cangnan Kaiyisi ECommerce Technology Co., Ltd.; 

Yongkang Huiyun Commodity Co., Ltd.; 

Wuyi Loncin Bottle Co., Ltd.; Zhejiang 

Yongkang Unique Industry & Trade Co., 

Ltd.; Suzhou Prime Gifts Co., Ltd.; 

Hangzhou Yuehua Technology Co., Ltd.; 

Guangzhou Yawen Technology Co., 

Ltd.; Jinhua City Ruizhi E-Commerce 

Co., Ltd.; Wo Ma Te (Tianjin) 

International Trade Co., Ltd.; and 

Shenzhen City Yaxin General 

Machinery Co., Ltd. The ID also finds 

that no violation has been established as 

to respondents Shenzhen Huichengyuan 

Technology Co., Ltd.; Sinbada Impex 

Co., Ltd.; and Zhejiang Yuchuan 

Industry & Trade Co., Ltd. 

The ID contains the CALJ’s 

recommended determination on remedy 

and bonding (‘‘RD’’). The RD 

recommends issuance of a GEO with 

respect to the asserted patents and 

trademarks. The RD does not 

recommend issuance of any cease and 

desist orders. No petitions for review 

were filed. 

The Commission determined to 

review the subject ID in part. See 86 FR 

59424–26 (Oct. 27, 2021). Specifically, 

the Commission determined to review 

the ID’s finding that Hydro Flask has 

satisfied the economic prong of the 

domestic industry requirement under 

section 337(a)(3)(A). Id.; see ID at 89–92. 

On review, the Commission affirmed the 

ID’s finding that Hydro Flask has 

established a domestic industry under 

section 337(a)(3)(A). Id. The 

Commission also requested written 

submissions on remedy, the public 

interest, and bonding. Id. 

On November 4, 2021, Complainants 

and OUII filed their opening written 

submissions on remedy, the public 

interest, and bonding. On November 12, 

2021, OUII filed its responsive written 

submission. No other submissions were 

received by the Commission. 

Having reviewed the submissions 

filed in response to the Commission 

request for briefing and the evidentiary 

record, the Commission has determined 

that the appropriate form of relief in this 

investigation is a GEO prohibiting the 

unlicensed importation of certain 

vacuum insulated flasks and 

components thereof that infringe the 

sole claims of the D’468, D’012, and 

D’320 patents and the ’784, ’365, and 

’888 trademarks. 

The Commission has further 

determined that the public interest 

factors enumerated in subsection (d)(1) 

(19 U.S.C. 1337(d)(1)) do not preclude 

issuance of the above-referenced 

remedial order. Finally, the Commission 

has determined that a bond in the 

amount of one hundred (100) percent of 

the entered value is required to permit 

temporary importation of the articles in 

question during the period of 

Presidential review (19 U.S.C. 1337(j)). 

The investigation is terminated. 

The Commission’s order and the 

record upon which it based its 

determination were delivered to the 

President and to the United States Trade 

Representative on the day of their 

issuance. The Commission has also 

notified the Secretary of the Treasury of 

the order. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended, 19 U.S.C. 1337, and in part 

210 of the Commission’s Rules of 

Practice and Procedure, 19 CFR part 

210. 

The Commission vote for this 

determination took place on January 5, 

2022. 

By order of the Commission. 

Issued: January 5, 2022. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2022–00281 Filed 1–10–22; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–939] 

Bulk Manufacturer of Controlled 

Substances Application: Curia 

Missouri Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Curia Missouri Inc. has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before March 14, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

March 14, 2022. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on August 19, 2021, Curia 

Missouri Inc., 2460 West Bennett Street, 

Springfield, Missouri 65807, applied to 

be registered as a bulk manufacturer of 

the following basic class(es) of 

controlled substance(s): 

Controlled 

substance Drug code Schedule 

Gamma Hydroxybutyric Acid.2010 I 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 7 / Tuesday, January 11, 2022 / Notices 1435 

Controlled substance Drug code Schedule 

Amphetamine ... 1100 II 

Lisdexamphetamine.1205 II 

Methylphenidate 1724 II 

Phenylacetone .. 8501 II 

Tapentadol ........ 9780 II 

The company plans to bulk 

manufacture the above-listed controlled 

substances in bulk for distribution to its 

customers. No other activities for these 

drug codes are authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2022–00325 Filed 1–10–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–942] 

Bulk Manufacturer of Controlled 

Substances Application: Johnson 

Matthey, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Johnson Matthey, Inc., has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before March 14, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

March 14, 2022. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on November 2, 2021, 

Johnson Matthey, Inc., 2003 Nolte Drive 

West Deptford, New Jersey 08066–1742, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled Substance Drug 

Code Schedule 

Gamma Hydroxybutyric Acid .. 2010 I 

Marihuana ............................... 7360 I 

Tetrahydrocannabinols ........... 7370 I 

Noroxymorphone .................... 9145 I 

Difenoxin ................................. 9168 I 

Amphetamine .......................... 1100 II 

Methamphetamine .................. 1105 II 

Lisdexamfetamine ................... 1205 II 

Methylphenidate ...................... 1724 II 

Nabilone .................................. 7379 II 

4-Anilino-N-Phenethyl-4-Piperidine (ANPP).8333 II 

Norfentanyl .............................. 8366 II 

Cocaine ................................... 9041 II 

Codeine ................................... 9050 II 

Dihydrocodeine ....................... 9120 II 

Oxycodone .............................. 9143 II 

Hydromorphone ...................... 9150 II 

Diphenoxylate ......................... 9170 II 

Ecgonine ................................. 9180 II 

Hydrocodone ........................... 9193 II 

Levorphanol ............................ 9220 II 

Meperidine .............................. 9230 II 

Methadone .............................. 9250 II 

Methadone intermediate ......... 9254 II 

Morphine ................................. 9300 II 

Thebaine ................................. 9333 II 

Opium tincture ........................ 9630 II 

Oxymorphone ......................... 9652 II 

Noroxymorphone .................... 9668 II 

Alfentanil ................................. 9737 II 

Remifentanil ............................ 9739 II 

Sufentanil ................................ 9740 II 

Tapentadol .............................. 9780 II 

Fentanyl .................................. 9801 II 

The company plans to bulk 

manufacture the listed controlled 

substances for the internal use 

intermediates or for sale to its 

customers. In reference to drug codes 

7360 (Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. The company plans to bulk 

manufacture for either internal usage as 

intermediates or to sale to customers as 

Active Pharmaceutical Ingredients 

(API). No other activities for these drug 

codes are authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2022–00326 Filed 1–10–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–944] 

Importer of Controlled Substances 

Application: Nexus Pharmaceuticals, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Nexus Pharmaceuticals, Inc. 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before February 10, 2022. Such 

persons may also file a written request 

for a hearing on the application on or 

before February 10, 2022. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on October 25, 2021, 

Nexus Pharmaceuticals, Inc., 10300 

128th Avenue, Pleasant Prairie, 

Wisconsin 53158–7338, applied to be 

registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled 

substance Drug code Schedule 

Remifentanil ...... 9739 I 

The company plans to import the 

listed controlled substance for research 

and analytical testing purposes. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. No other activity for 

this drug code is authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2022–00329 Filed 1–10–22; 8:45 am] 

BILLING CODE P 


khammond on DSKJM1Z7X2PROD with NOTICES